TMEM106B antibody - 506 017 K.O.

TMEM106B forms amyloid-like fibrils in human brain

Rat monoclonal purified IgG

Cat. No.: 506 017

Amount: 100 µg

Price: $420.00

Cat. No. 506 017	100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: external data (see remarks) gallery IP: not tested yet ICC: not tested yet IHC: not tested yet IHC-P: 1 : 1000 up to 1 : 2000 gallery Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section. Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section. Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section. Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section. Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.
Clone	SY-118C4
Subtype	IgG2a (κ light chain)
Immunogen	Synthetic peptide corresponding to AA 239 to 252 from human TMEM106B (UniProt Id: Q9NUM4)
Epitop	AA 239 to 252 from human TMEM106B (UniProt Id: Q9NUM4)
Reactivity	Reacts with: human (Q9NUM4), mouse (Q80X71). Other species not tested yet.
Specificity	K.O. validated PubMed: 39709600
Remarks	WB: This antibody has not yet been successfully tested for this application using our standard protocol, but has been published by customers (see “application” references and gallery). This antibody shows an additional unspecific band at 70kD. IHC-P: Antigen retrieval with Tris-EDTA buffer pH 9, followed by formic acid treatment, is required.
Data sheet	506_017.pdf

References for TMEM106B - 506 017

Physiological shedding and C-terminal proteolytic processing of TMEM106B.
Held S, Erck C, Kemppainen S, Bleibaum F, Giridhar NJ, Feederle R, Krenner C, Juopperi SP, Calliari A, Mentrup T, Schröder B, et al.
Cell reports (2024) 441: 115107. 506 017 WB, IHC-P; KO verified; tested species: human,mouse

Cat. No.: 506 017

Amount: 100 µg

Price: $420.00

IHC-P

Background

TMEM106B or Transmembrane protein 106B is a lysosomal type II transmembrane protein which has been identified by a genome-wide association study as a potential risk factor for a neurodegenerative disorder called frontotemporal lobar degeneration (FTLD)(1). The C-terminal luminal domain of TMEM106B undergoes a proteolytic cleavage that forms sarkosyl-insoluble amyloid-like fibrils (residues 120-254) in human brains (2). TMEM106B is ubiquitously expressed, but the function of TMEM106B is almost unknown. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry (3).

1 ) Van Deerlin VM et al., Nat Genet (2010)
2 ) Schweighauser M et al., Nature (2022)
3 ) Baggen J et al., Cell (2023)

Protocols

IHC-P